BPC November 22 update

EyeGate EYEG shares rise on Ocular Bandage Gel data

Price and Volume Movers

EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) shares closed up 48% to $7.09 following its announcement of data from its trial using the Ocular Bandage Gel ("OBG") eye drop which showed superiority over standard-of-care in its corneal wound repair pivotal study.

ASLAN Pharmaceuticals (NASDAQ: ASLN) shares closed up 293% to $1.73 following a press release noting pre-clinical data from its candidate ASLAN003 has been published in the November issue of Haematologica Journal. Earlier this month shares of the company lost over half of their value on news top-line data from its Phase 2/3 TreeTopp trial of varlitinib in patients with biliary tract cancer, did not met the primary endpoints of progression-free survival (PFS) and overall response rate (ORR).

Roche (OTCQX:RHHBY) and Spark Therapeutics, Inc. (NASDAQ:ONCE) announced that another extension of the offering period to purchase all of the outstanding shares of Spark for $114.50 per share. The new extension, its 9th delay, runs through to December 10, 2019.

-

Major price movers (stocks priced > $1.00, volume > 50k):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume

ADVANCERS:

DelMar Pharmaceuticals Inc (DMPI): $1.05; +27%.

Verastem Inc (VSTM): $1.12; +24%.

Akebia Therapeutics Inc (AKBA): $4.21; +22%.

Axovant Gene Therapies (AXGT): $5.66; +21%.

Adamis Pharmaceuticals Corp (ADMP): $1.26; +18%.

DECLINERS:

Mereo BioPharma (MREO): $2.10; -16%.

Recro Pharma Inc (REPH): $15.16; -13%.

Kodiak Sciences Inc (KOD): $25.62; -11%.

Satsuma Pharmaceuticals Inc (STSA): $15.40; -11%.

Cabaletta Bio Inc (CABA): $13.25; -9%.

Pipeline updates below:

Pipeline Database Updates

Drug Stage Catalyst Market Cap

ALNY – Alnylam Pharmaceuticals Inc.
Lumasiran (ALN-GO1) ILLUMINATE-B
Primary Hyperoxaluria Type 1

Phase 3 Phase 3 top-line data due mid-2020.
$13.8 billion

ALNY – Alnylam Pharmaceuticals Inc.
Patisiran APOLLO-B
Wild-type ATTR amyloidosis patients with cardiomyopathy

Phase 3 Phase 3 enrolment to be completed late-2020.
$13.8 billion

ALNY – Alnylam Pharmaceuticals Inc.
ALN-TTRsc02 (vutrisiran) - HELIOS-B
ATTR amyloidosis with cardiomyopathy

Phase 3 Phase 3 trial has been initiated - noted November 22, 2019.
$13.8 billion

EBS – Emergent Biosolutions Inc.
CHIKV-VLP
Chikungunya virus

Phase 2 Phase 2 interim analysis noted 98% of study participants produced a neutralizing antibody response against the chikungunya virus (CHIKV) within seven days after vaccination - November 22, 2019.
$2.8 billion

IMMP – Immutep Limited
GSK2831781
Ulcerative Colitis

Phase 2 Phase 2 trial to be completed August 2022.
$56.6 million